Inveready sells Zip to Bionaturis for €1.6m

As part of the deal, Inveready acquired 5% of Bionaturis's share capital. According to a statement, the acquisition will enable Zip to further develop its technology and boost its commercialisation.

Bionaturis is a Spanish public company focused on the biotech sector. The business develops vaccines and drugs for both humans and animals and has a presence in Spain, the US and China.

Previous funding
Inveready acquired a stake in the business through its Inveready Innvierte Biotech II vehicle in March 2015.

Company
Headquartered in Barcelona, Zip was founded in March 2015 following the rebranding of parent company Era Biotech.

The company develops a proprietary technology focused on protein production for the pharmaceutical sector. The business employs three people.

People
Inveready – Josep Maria Echarri (managing partner); Sara Secall (principal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Healthcare
• Southern Europe
• Spain
• Inveready First Capital
• Trade sale